Eli Lilly and Company

- The transcript does not specifically mention any new fundraising plans through debt or equity. - Financial guidance updates focus on revenue ranges, operating margins, investments in SG&A and R&D, and tax rates. - The company is investing heavily in supply capacity and demand generation but does not mention raising capital via debt or equity. - There is no explicit discussion of issuing new shares or taking on new debt in the periods covered. - The CFO discusses operating margin targets and growth investments but no mention of external fundraising. - Overall, no current or future debt or equity fundraising plans are disclosed in the provided excerpts.

- Lilly is continuing to scale up investments across manufacturing and commercial to support successful launches of new medicines like Mounjaro, Zepbound, Kisunla, and Ebglyss. - Significant investments have been made in parenteral filling capacity and API (Active Pharmaceutical Ingredient) capacity to support ramp-up in production; these efforts have a delivery timeline of two to four years. - Capacity expansion started in prior years (2021-2023) is progressing and expected to come fully online over the next few years to meet demand growth. - Ramp-up in supply capacity is accelerating during the current year with strong growth expected next year. - Investment in commercial activities, including SG&A and R&D, is being increased to drive demand generation and support pipeline progression into phases 2 and 3. - Capital expenditure includes continued build-out of manufacturing infrastructure to handle increased production volumes for launch and pipeline products.

- Eli Lilly expects strong revenue growth driven by new products like Mounjaro and Zepbound, with U.S. sequential quarter-over-quarter prescriptions increasing and demand growing globally. - They anticipate at least 50% growth in Q4 2024, supported by accelerating demand generation and expanded supply capacity. - New country launches outside the U.S. will also contribute to growth in 2025. - The company plans increased investments in SG&A and R&D to support further growth and demand stimulation activities. - Despite some channel inventory lumpiness observed in Q3, in-market consumption of key brands accelerates, with supply constraints easing. - Uptake in immunology, oncology, and other pipeline medicines is expected to complement sales growth. - Long-term operating margin expansion is anticipated, justified by these sustained investments and portfolio progress. - Supply capacity expansions, including recent investments in manufacturing, support projected strong growth.

- Lilly expects continued strong revenue growth driven by new products like Mounjaro, Zepbound, Jaypirca, Kisunla, and Ebglyss. - Q4 2024 guidance anticipates around 50% revenue growth driven mainly by incretin medicines. - Operating margin expected to expand in the short term due to increased investment in SG&A and R&D. - Long-term operating margin growth is planned, aligned with sustained investments to support product launches and R&D. - EPS for Q3 2024 was $1.19, up from $0.10 in Q3 2023, despite negative impacts from acquired IPR&D charges. - Lilly foresees acceleration in demand generation efforts translating to prescription growth, especially moving into 2025. - The company is confident about its pipeline and manufacturing investments supporting profitable growth. - Overall, Lilly projects sustained earnings growth fueled by launches, market expansion, and investment in innovation.

The transcript does not explicitly provide details on current or expected orderbook or pending orders for Eli Lilly. However, relevant insights include: - Strong revenue growth cited for key products like Mounjaro and Zepbound. - Demand generation efforts are being accelerated with improved supply capacity. - Supply constraints were significant in early 2025 but have largely eased. - Lilly is witnessing more than 25% sequential quarterly growth in prescriptions (TRx) for Mounjaro and Zepbound. - Supply capacity expansions are ongoing with expectations of strong growth next year. - U.S. and OUS (Outside U.S.) launches scheduled and being planned to support continued uptake. - Discussions reference inventory dynamics and channel stocking variability, but no direct mention of a backlog or pending order book. - Overall demand is strong, and supply is being gated to match demand stimulation efforts to avoid overstocking. In summary, while specific orderbook figures aren't given, the company exhibits strong demand with expanding supply to support accelerated growth.